| MANAGEMENT DISCUSSION AND ANALYSIS |
|
 |
|
| This year too, there was a continuation of early-stage outlicensing deals that involved Indian companies and the transfer of intellectual property. In recognition of the high quality skill base available in India, and flexibility to shift parts of large projects across continents as also reduce costs substantially, a large number of European and US companies set up R&D centers in India. This move, with the other emergent trend of buying existing API units or setting up greenfield API units in India, will offer companies from the regulated markets an opportunity to compete on the same cost base and access the same expertise. This also implies that the competition for talent is increasing as also the pressure on resources required to remain world-class. |
|
| Last year, in our report to you, we had highlighted about the addition of about 250,000 sq ft of research floor area across two high capability sites, SPARC or the Sun Pharma Advanced Research Center, in Baroda and in Mumbai. As more labs were commissioned, the number of labs has increased from 137 last year to 161. |
|
 |
| SPARC, Baroda |
|
| Our focus for the short term is on projects for India and the neighboring markets. This year, SPARC helped to bring to market 32 products in India, of which 11 were based on a delivery system advantage or complex development technology. |
|
| In addition, as we slowly ramp up in international markets, new filings were made in international markets to offer a pipeline that supports our current product basket. The number of active registrations stood at 463, with 730 products being marketed. |
|
| Some of these international filings are for complex delivery system based products, like the anticancer liposomal doxorubicin Lipodox, and Lupride, the one and three-month depot injectable used in cancer and fertility treatments. |
|
|
|
|
|
News Articles
Contact Us
